SCHEMBL5158992

SCHEMBL5158992

COc1ccccc1C(=O)NC[C@H](C)c1ccccc1

nearest known ligand 0.76

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 1/20 0.76
NPC1 O15118 2/20 0.66
RAB9A P51151 2/20 0.66
HPGD P15428 3/20 0.63
ALDH1A1 P00352 2/20 0.63
TP53 P04637 1/20 0.61
GLA P06280 1/20 0.61
MAPK1 P28482 1/20 0.57
CTSD P07339 1/20 0.56
HCN1 O60741 1/20 0.53
HCN4 Q9Y3Q4 1/20 0.53
POLB P06746 1/20 0.52
P2RX7 Q99572 1/20 0.52
ROCK2 O75116 2/20 0.52
ROCK1 Q13464 2/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7976400 1.00 KCNA3 (0.76) KCNA3NPC1RAB9AHPGDALDH1A1
SCHEMBL5157294 0.88 KCNA3 (0.75) KCNA3NPC1RAB9AHPGDALDH1A1
SCHEMBL14976803 0.88 KCNA3 (0.60) KCNA3NPC1RAB9AHPGDALDH1A1
SCHEMBL10330502 0.85 KCNA3 (0.70) KCNA3NPC1RAB9AHPGDALDH1A1
SCHEMBL4965050 0.84 KCNA3 (0.69) KCNA3NPC1RAB9AHPGDALDH1A1
SCHEMBL5159523 0.83 KCNA3 (0.68) KCNA3NPC1RAB9AHPGDALDH1A1
SCHEMBL5159459 0.83 KCNA3 (0.68) KCNA3NPC1RAB9AHPGDALDH1A1
SCHEMBL5162069 0.81 KCNA3 (0.65) KCNA3NPC1RAB9AHPGDALDH1A1
SCHEMBL7976348 0.81 KCNA3 (0.65) KCNA3NPC1RAB9AHPGDALDH1A1
SCHEMBL6207609 0.81 NPC1 (0.71) KCNA3NPC1RAB9AHPGDTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1126836-B1 BENZAMIDE POTASSIUM CHANNEL INHIBITORS MERCK & CO INC (US) 2007-02-14 EP disclosed
US-6194458-B1 1-(2-METHOXYPHENYL)-1-OXO-2-AZA-(S)-4-I-BUTYL-4-PHENYLBUTANE, FOR EXAMPLE; TREATING VARIOUS CONDITIONS INCLUDING TRANSPLANTATION REJECTION OF ORGANS OR TISSUES IN A PATIENT; IMMUNOSUPPRESSANT COMPOSITIONS MERCK & CO., INC. 2001-02-27 US disclosed